2019年新冠肺炎患者中阿兹武丁和死亡率:一项回顾性队列研究
Bin Liu1, Mingjin Yang2, Li Xu2
1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Youyi Rd 1, Yuzhong, Chongqing 400016, China; Department of Respiratory and Critical Care Medicine, Zhuzhou Central Hospital, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, No. 116, Changjiang South Road, Tianyuan District, Zhuzhou, Hunan 412007, China.
International immunopharmacology
|August 26, 2023
概括
阿兹丁 (FNC) 在COVID-19患者中显著降低了28天的死亡率. 这种抗病毒治疗证明了保护作用,降低了2019年冠状病毒病患者住院死亡的风险.
科学领域:
- 病毒学 病毒学
- 临床医学 临床医学
- 药理学 药理学 是一个学科.
背景情况:
- 已知阿兹武丁 (FNC) 在体外和体内抑制SARS-CoV-2复制.
- 对于FNC对COVID-19患者死亡风险的影响尚不清楚.
- 这项研究调查了FNC对住院COVID-19患者28天死亡率的影响.
研究的目的:
- 确定阿兹武丁 (FNC) 管理是否降低了COVID-19患者死亡风险.
- 分析FNC治疗与28天死亡率之间的关联.
- 评估二次结果,包括ICU入院和停留时间.
主要方法:
- 对1110名住院患者进行了回顾性队列研究,确认了COVID-19.
- 用FNC治疗的患者与未接受治疗的患者之间的28天死亡率的比较.
- 使用反向概率权重 (IPW) 和倾向得分匹配的多变量分析.
主要成果:
- 治疗FNC与较低的原始28天死亡率 (12.7%与23.6%) 有关.
- 经过调整的分析,包括IPW和倾向性得分匹配,证实FNC使用后28天死亡率显著降低.
- 在不同的分析模型中,28天死亡率的几率比率从0.438到0.754不等,所有这些都表明了有益的影响.
结论:
- 阿兹丁 (FNC) 的使用与COVID-19患者28天死亡率显著降低有关.
- FNC在改善住院COVID-19患者的生存结果方面显示出潜在的治疗益处.
- 进一步的研究可能会阐明FNC在管理COVID-19中的精确机制和最佳使用.
更多相关视频
相关概念视频
Acute Respiratory Failure-V
161
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
161
Acute Respiratory Failure-I
244
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
244
Acute Respiratory Failure-II
270
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
270
Acute Respiratory Failure-III
219
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
219
Acute Respiratory Failure-IV
176
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
176
Coronary Artery Disease IV: Preventive Measures
23
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23


